Galderma and GME Agree to a New Collaboration
Swiss pharmaceutical company Galderma SA and German MedTech company German Medical Engineering (GME) have agreed to collaborate in the field of photodynamic therapy (PDT).
PDT utilizes a light-activated agent (photosensitizer) to destruct tumour cells⁽¹⁾. Galderma’s product Metvix® is such a photosensitizer, while GME’s system MultiLite® is used to activate the agent during therapy. The most common indications for PDT in dermatology are the treatment of actinic keratosis and squamous cell carcinoma in situ (Bowen disease) and basal cell carcinoma (BCC), both forms of non-melanoma skin cancer (NMSC).
Metvix® & MultiLite®
MultiLite® can activate Metvix® with two light protocols: the conventional protocol (C-PDT) with red light which can be used to treat actinic keratosis (AK) and NMSC, and the Artificial Daylight (ADL-PDT) protocol with artificial daylight which can be used for AK. The collaboration will start in the European Union, the United Kingdom, Switzerland and Norway.
Beyond the fact that MultiLite® can activate both red and artificial daylight protocols for Metvix®, MultiLite® will feature a specific ADL treatment protocol designed for use with the Galderma product Metvix®. This 120-minute treatment protocol will be integrated software-wise and represents a convenient feature for users of the lamps.
The full potential of MultiLite®
Stefan Schulze, Managing Director of GME, is very pleased about the partnership:
“I am glad to cooperate with Galderma: the global leader in photodynamic therapy. MultiLite® is emitting light with three different colours each generated by dedicated LED. This concept allows us to offer both C-PDT and ADL-PDT with one device and to combine a small footprint with a large treatment area.”
Conventional and Artificial Daylight with one device
Olivier Jean Baptiste Baldanza, Galderma’s Global Head of Prescription New Products, Non-Melanoma Skin Cancer and Legacy Brands, comments:
“GME’s MultiLite® offers a very important option for healthcare professionals to activate Metvix® with both C- and ADL protocols in one device. Furthermore, the customised feature for ADL represents a simple solution to perform the selected treatment procedure”
¹ B Dreno. Management of actinic keratosis: a practical report and treatment algorithm from AKTeamTM expert clinicians. JEADV 2014, 28, 1141–1149